NCT04027647 - Phase 2 Study of Dacomitinib in NSCLC | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

NSCLC Stage IIIBNSCLC Stage IIICNSCLC Stage IVRecurrent NSCLCEGFR Positive Non-Small Cell Lung Cancer

Interventions

DRUG

Dacomitinib

30mg of oral dacomitinib is administered daily for one cycle. After one cycle, a toxicity assessment will be conducted. Subjects will then continue dacomitinib at either 30mg or 45mg.

Trial Locations (9)

Unknown

Prince of Wales Hospital, Hong Kong

Sarawak General Hospital, Kuching

University Malaya Medical Centre, Kuala Lumpur

Beacon Hospital, Petaling Jaya

National Cancer Centre Singapore, Singapore

Dong-A University Hospital, Busan

Seoul National University Hospital, Seoul

Phramongkutklao Hospital, Bangkok

Ramathibodi Hospital, Bangkok